Title : Prospective Study - Prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis.
link : Prospective Study - Prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis.
Prospective Study - Prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis.
This study investigated the prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis. Is such damage reversible following treatment with DAAs?
Full-text article available online @ Medscape , free registration required, or purchase article, here.
Aliment Pharmacol Ther. 2018 Oct;48(7):740-749. doi: 10.1111/apt.14934. Epub 2018 Aug 10.
Subclinical cardiovascular damage in patients with HCV cirrhosis before and after treatment with direct antiviral agents: a prospective study.
Novo G1, Macaione F1, Giannitrapani L2, Minissale MG2, Bonomo V1, Indovina F1, Petta S3, Soresi M2, Montalto G2, Novo S1, Craxi A3, Licata A2,3.Abstract
BACKGROUND:
Cirrhosis is associated with morpho-functional cardiovascular alterations.
AIMS:
To detect early features of cardiovascular damage in HCV-compensated cirrhotic patients using myocardial deformation indices and carotid arterial stiffness, and, further, to evaluate their short-term behaviour after HCV eradication with direct antiviral agents (DAAs).METHODS:
Thirty-nine consecutive patients with HCV cirrhosis, without previous cardiovascular events, were studied and matched for age, gender and cardiovascular risk factors to 39 controls without liver or cardiovascular disease. Patients and controls underwent a baseline echocardiographic evaluation including global longitudinal strain and ultrasound scan of carotid arteries. HCV-cirrhotics were reassessed by echocardiography and carotid ultrasound after obtaining sustained virological response (SVR) on DAAs.RESULTS:
HCV-cirrhotics showed at baseline a significantly reduced global longitudinal strain compared to controls -18.1 (16.3-20.5) vs -21.2 (20.4-22.3), P < 0.001. They also had a significantly higher pulse wave velocity 8.6 (7.7-9.1) m/s vs 6.6 (6.0-7.1) m/s, P = 0.0001, and β-stiffness index 12.4 (11.1-13.5) vs 8.6 (8.0-9.2) P = 0.0001. At multiple regression analysis, diabetes and HCV cirrhosis were independent predictors of global longitudinal strain. All HCV-cirrhotic patients had SVR on DAAs. Follow-up available in 32 of 39 (82%) at 9 (8-10) months showed a significant improvement of tricuspid annular plane systolic excursion (P = 0.01) and lateral E' velocity compared to baseline (P = 0.001).CONCLUSIONS:
HCV-cirrhotics show a significant rate of subclinical cardiac and vascular abnormalities. At a time when their survival is less linked to progression of liver disease, due to viral eradication on DAAs, cardiovascular morbidity and mortality may take a significant role.
Continue to full-text: https://www.medscape.com/viewarticle/902665
On This Blog
A collection of current research articles on ailments related to HCVArticle directory on the extrahepatic manifestations of hepatitis C.
Thus Article Prospective Study - Prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis.
That's an article Prospective Study - Prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis. This time, hopefully can give benefits to all of you. well, see you in posting other articles.
You are now reading the article Prospective Study - Prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis. with the link address https://theleknews.blogspot.com/2018/10/prospective-study-prevalence-of-early.html
0 Response to "Prospective Study - Prevalence of early signs of cardiovascular damage in patients with HCV cirrhosis."
Post a Comment